The next generation of antibody-drug conjugates (ADCs) is redefining targeted cancer therapy, offering unprecedented precision and efficacy. As the industry pushes the boundaries of innovation, strategic collaboration is more critical than ever. Partnerships between biotech firms, pharmaceutical companies, and investors play a crucial role in accelerating development, optimizing commercialization, and ensuring that cutting-edge therapies reach the patients who need them most.
Over the past several years, there has been a noticeable rise in deals involving ADCs, including licensing agreements, research collaborations, and options to license (see Figure below, left panel). This surge reflects the growing confidence in ADC technology as a viable and innovative therapeutic approach across oncology. It also highlights the increasing recognition of ADCs as a transformative treatment modality, particularly in areas with high unmet medical needs, such as hematologic malignancies and solid tumors.
Key Drivers of Growth in ADC Partnerships
The increase in ADC-focused partnerships highlights advancements in several key areas:
- Precision Targeting: Advances in antibody engineering and conjugation technologies have enabled more selective targeting of tumor cells, minimizing off-target effects and enhancing therapeutic outcomes [1].
- Payload Optimization: Innovations in linker-payload chemistry have improved the stability and efficacy of ADCs, allowing for more potent and safer drug delivery [2].
- Reducing Off-Target Toxicity: Novel linker strategies and site-specific conjugation techniques have contributed to improved safety profiles, making ADCs more tolerable for patients [3][4][5].
- Regulatory Advancements: Regulatory agencies have shown increased receptivity to ADCs, with accelerated approvals for promising candidates, further driving investment and interest in the field [6].
These innovations are driving both clinical successes and commercial interest, reshaping competitive dynamics in the biopharmaceutical landscape. [7][8][9] As a result, ADCs are not only being explored in oncology but also in other therapeutic areas, including autoimmune diseases and infectious diseases, broadening their potential market impact.
The Role of China in ADC Development
A significant trend in the ADC space is the growing participation of China-headquartered companies in ADC-related deals (see Figure above, right panel). This involvement is mainly characterized by out-licensing ADC assets to Western-based companies, underscoring the rapid progress in R&D capabilities within China’s biopharma sector [10]. Several factors contribute to this trend:
- Increased R&D Investment: China’s government and private sector have significantly increased funding for biotechnology innovation, fostering a robust pipeline of ADC candidates [11].
- Regulatory Reforms: Streamlined approval processes and alignment with global regulatory standards have encouraged cross-border collaboration and investment [12].
- Strategic Market Expansion: By partnering with Western companies, Chinese biopharma firms can gain access to global markets while leveraging their expertise in cost-efficient ADC development [13].
These developments have positioned China-based companies as influential players, contributing to a more globalized and competitive market landscape [10]. Their presence in the ADC ecosystem is not only fostering innovation but also accelerating the availability of novel therapies worldwide [14].
The Importance of Strategic Partnerships in ADC Development
The increase in partnerships boosts access to diverse pipelines, accelerates innovation cycles, and expands ADCs’ therapeutic applications. For biotech and pharmaceutical companies, strategic collaborations provide:
- Faster Development Timelines: By leveraging each partner’s expertise, ADCs can move through preclinical and clinical stages more efficiently.
- Risk Mitigation: Sharing financial and developmental risks makes it easier to pursue high-potential but complex ADC projects.
- Regulatory and Commercial Expertise: Partnering with experienced companies can facilitate regulatory approvals and optimize commercialization strategies.
How JEA BizDev Consulting Can Support ADC Strategic Partnerships
At JEA BizDev Consulting, we specialize in advancing novel ADC assets through strategic partnerships that accelerate development and commercialization. With a client portfolio of promising Best-in-Class or First-in-Class ADC candidates (see Table 1 below), we are seeking strategic partners to help bring these therapies to patients in need. Our expertise spans:
- Proficient across the entire business development value chain (Strategy, Search & Evaluation, Deal Structuring, Negotiation, Alliance Management)
- Facilitating licensing agreements, research collaborations, and investment opportunities.
- Providing strategic advisory services to optimize deal structures and partnership models.
- 25+ years of experience, over 80+ partnerships established, over $20B+ in transaction value.
- Forged strategic partnerships for a portfolio of ADC assets from CSPC Pharmaceutical Group, driving cumulative transaction value exceeding $3B, including collaborations with:
- Radiance Biopharma (ROR1-ADC, 2025)
- Corbus Pharmaceuticals (Nectin4-ADC, 2023)
- Elevation Oncology (Claudin18.2-ADC, 2022).
Partnering Opportunities
We invite biotech and pharmaceutical companies, as well as investors, to explore collaboration opportunities with us. Whether through co-development, licensing, or strategic investment, we are keen to partner with organizations committed to revolutionizing ADC therapeutics. The continued success of ADCs relies on collaborative efforts that leverage the expertise of multiple stakeholders, to bring these innovative therapies to patients in need.
Strategic partnerships are the driving force behind innovation in the ADC space. As the field continues to evolve, collaborations between biotech firms, pharmaceutical giants, and investors will remain essential in shaping the future of precision oncology and beyond. With JEA BizDev Consulting facilitating these critical connections, the next wave of transformative ADC therapies is within reach through strategic partnerships.
- A range of ADC candidates with distinct mechanisms of action, optimized payloads, and strong preclinical or clinical validation are available for review.
- Technical decks and further details can be shared upon request.
|  |
Reference
[1] Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018 Jan;9(1):33-46. doi: 10.1007/s13238-016-0323-0. Epub 2016 Oct 14. PMID: 27743348; PMCID: PMC5777969.PMC+1PubMed+1
[2] Kostova V, Désos P, Starck JB, Kotschy A. The Chemistry Behind ADCs. Pharmaceuticals (Basel). 2021 May 7;14(5):442. doi: 10.3390/ph14050442. PMID: 34067144; PMCID: PMC8152005. PMC
[3] Agarwal P, Bertozzi CR. Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development. Bioconjug Chem. 2015 Feb 18;26(2):176-92. doi: 10.1021/bc5004982. Epub 2015 Jan 30. PMID: 25494884; PMCID: PMC4335810. ACS Publications
[4] Dennler P, Chiotellis A, Fischer E, Brégeon D, Belmant C, Gauthier L, Lhospice F, Romagne F, Schibli R. Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates. Bioconjug Chem. 2014 Mar 19;25(3):569-78. doi: 10.1021/bc400574z. Epub 2014 Feb 12. PMID: 24483299.ACS Publications
[5] McCombs JR, Owen SC. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. AAPS J. 2015 Mar;17(2):339-51. doi: 10.1208/s12248-014-9710-8. Epub 2015 Jan 22. PMID: 25604608; PMCID: PMC4365093.PMC
[6] Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337. doi: 10.1038/nrd.2016.268. Epub 2017 Mar 17. PMID: 28303026.
[7] Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA; DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251. doi: 10.1056/NEJMoa2112431. Epub 2021 Sep 18. PMID: 34534430; PMCID: PMC9066448.New England Journal of Medicine
[8] Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I; DESTINY-Breast01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11. PMID: 31825192; PMCID: PMC7458671.
[9] Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, Hirata J, Penuel E, Paulson JN, Cheng J, Ku G, Matasar MJ. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020 Jan 10;38(2):155-165. doi: 10.1200/JCO.19.00172. Epub 2019 Nov 6. PMID: 31693429; PMCID: PMC7032881.
[10] Versel, N. (2024, April 1). Chinese ADC Investment Boom in Question With China-U.S. R&D Relations in Flux. BioSpace. BioSpace
[11] (2024, May 6). Chinese companies lead ADC development pipeline, reveals GlobalData. GlobalData
[12] UBS Global. (2023). APAC Focus: China ADC drugs—a rising force in cancer treatment. UBS. United States of America
[13](2024, January 29). Antibody drug conjugates focus draws global pharma giants attention to China, says GlobalData. GlobalData. GlobalData
[14] Neville, S., & Palma, S. (2025, March). Rapid Trials Prompt Deals Rush for Chinese ‘Super Me-Too’ Drugs. Financial Times.
Featured imagelicensed under the Unsplash+ License.
DOI
